Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with statin therapy, resulted in a 56% reduction in low density lipoprotein cholesterol, the "bad" cholesterol, in patients with heterozygous familial hypercholesterolemia. The study was published in Circulation and presented at the American Heart Association Scientific Sessions 2012.